This publication has been discontinued on July 19, 2011.
Molecular diagnostics are seen as being a major breakthrough in medical
science. While the technology itself has broad applications to such areas as
agricultural bioterrorism and environmental science, medical and medical
research applications have provided the primary focus. As a result, great things
have been predicted for the development and use of new therapeutics based on
molecular testing approaches.
The primary molecular diagnostics approaches are
based on two major database sciences (genomics and proteomics) and their
relationship to disease and metabolic processes (functional genomics and
functional proteomics). The genome or proteome that forms the basis for these
tests is very often of human origins, but may also be from a pathogen. As a
result, the breadth of application for molecular diagnostic is virtually
unlimited. With all this opportunity, however, progress has been slow in the
development, introduction and commercialization of molecular diagnostics. This
has been related to the difficulty and expense of performing such assays, and
the utility of the test procedures in the absence of substantive therapeutic
options based on the additional data provided by these assays.
This study
looks at the basis for molecular diagnostics in the fields of genomics and
proteomics; the technologies that are used to apply genomic and proteomic data
to the diagnosis of disease; the diseases and conditions that are primary and
secondary targets for this technology; the economics of molecular diagnostic
testing; and its potential impacts on medical practice and the diagnostics
markets over the next ten years. Number of tests, market potential, and
estimated cost per test is provided for each test for each of the 10 years.
Chapter I: Executive Summary
- Background
- Scope and Methodology
- Size and Growth of Market
- Competitive Picture
- Market Trends and Factors
Chapter II: Introduction
- Background
- Diagnostics and Their Use
- Clinical relevance
- Scientific Limitations
- Cost-Benefit Relationships
- Major Influencing Technologies
- Genetics
- Genomics
- Proteomics
Chapter III: Molecular Diagnostics Technologies
- Background
- Amplification Technologies
- Blotting Technologies
- Electrophoretic Technologies
- Microchip Technologies
- Probe Technologies
- RNAi Analysis
- Single Nucleotide Polymorphism (SNP) Analysis
Chapter IV: Applications of Molecular Diagnostics
- The Testing Environment
- Commercial Laboratories
- University/Hospital Laboratories
- Blood Banking Analysis
- Cancer Diagnosis and Treatment Selection
- Genetic Diseases
- Pharmacogenetics
- Pharmacogenomics
Chapter V: The Market for Molecular Diagnostics
- Market Size and Trending
- Competitive Picture and Industry Structure
- Future Prospects
- Chapter VI: Company Profiles
- Abbott Diagnostics
- Affymetrix Inc.
- Agilent Technologies, Inc.
- Applied Biosystems Group
- Cepheid, Inc.
- Chiron Corporation
- diaDexus LLC
- Digene Corp.
- Gene Logic, Inc.
- Gen-Probe Incorporated
- Innogenetics NV
- MitoKor, Inc.
- Molecular Diagnostics, Inc.
- Myriad Genetics, Inc.
- Nanogen, Inc.
- Orchid Biosciences, Inc.
- Perkin-Elmer Corp.
- Roche Diasgnostics Division/Roche Molecular Systems
- Sangtec AB
- Visible Genetics
Chapter VII: Conclusions and Strategic Implications
APPENDIX A: Glossary
APPENDIX B: Company Names and Addresses
